Small caps round up: Intandem, Digital Learning, Hornby ...

Intandem Films, the London and Los Angeles based international film group, will co-produce 10 Things I Hate About Life, and sell the film internationally. The company will also distribute the film in the UK. The script has been written and the film will be directed by Gil Junger, the director of the globally successful 10 Things I Hate About You starring the late Heath Ledger.

By
published
in Features

Intandem Films, the London and Los Angeles based international film group, will co-produce 10 Things I Hate About Life, and sell the film internationally. The company will also distribute the film in the UK. The script has been written and the film will be directed by Gil Junger, the director of the globally successful 10 Things I Hate About You starring the late Heath Ledger.

Model train and Scalextric slot-racing games maker Hornby has indicated that underlying profit before tax for the year to the end of March will be not less than £4.5m after a subdued finish to the financial year. The market was expecting full-year profit before tax of £6.45m prior to the latest trading update, which is sure to be interpreted as a profits warning. The group's international business traded strongly in the first three months of the year and made a positive contribution, the group said. "The performance of our international business continues to improve and our London 2012 Games range of merchandise is proving to be increasingly popular," said Neil Johnson, Chairman of Hornby.

Digital Learning Marketplace (DLM), which makes education software, has acquired the global distribution rights to a so-called "employee engagement tool" created by People First. The programme, called "An Even Better Place to Work" will now be digitised and "gamified" by DLM which also takes over ongoing contracts with customers including the NHS, Siemens, Emirates, and Black & Decker.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Angle, the technology commercialisation company, has passed another milestone in its development plan for Parsortix cell separation technology by using a Parsortix diagnostic device to successfully capture breast cancer tumour cells. The device has now been used to capture both prostate cancer and breast cancer cells in patient blood, the most common cancers in men and women respectively.

BS

MoneyWeek
Latest